An expert discusses how patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) now have several ...

Excitement is building as a new treatment for advanced bladder cancer that doubles survival time has been approved for NHS ...

Treatment for advanced bladder cancer had not significantly changed for 40 years. Now thousands are set to benefit ...

THOUSANDS of Brits with bladder cancer could survive for twice as long after a new treatment was given the green light to be ...

New trial results reveal enfortumab vedotin and pembrolizumab significantly improve survival for muscle-invasive bladder ...

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...

NHS approves new enfortumab vedotin and pembrolizumab combo for advanced bladder cancer, doubling survival rates and offering ...

NICE has recommended a new first-line treatment for adults with advanced bladder cancer, marking a significant breakthrough for patients facing this devastating disease.

Professor Peter Johnson, NHS England’s National Clinical Director for Cancer, said: “This is one of the most hopeful advances in decades for people with bladder cancer who will now be offered a ...

They randomly assigned 702 patients with high-risk, muscle-invasive bladder cancer who had undergone bladder-removal surgery to receive adjuvant therapy with pembrolizumab every three weeks for a ...

SAN FRANCISCO — Pembrolizumab monotherapy exhibited antitumor activity among certain patients with high-risk non-muscle-invasive bladder cancer, according to results of a single-arm phase 2 study.

Pembrolizumab, an anti-programmed death receptor-1 (PD-1) therapy, is marketed under the brand name Keytruda and is currently approved for 3 urothelial cancer indications: ...